Milestone Pharmaceuticals... (MIST)
1.98
0.02 (1.02%)
At close: Jan 15, 2025, 1:34 PM
undefined% (undefined)
| Bid | 1.97 |
| Market Cap | 105.32M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.8 |
| PE Ratio (ttm) | -2.47 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.98 |
| Volume | 170,341 |
| Avg. Volume (20D) | 502,319 |
| Open | 2.03 |
| Previous Close | 1.96 |
| Day's Range | 1.95 - 2.07 |
| 52-Week Range | 1.12 - 2.75 |
| Beta | undefined |
About MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and ...
Industry Biotechnology
Sector Healthcare
IPO Date May 9, 2019
Employees 47
Stock Exchange NASDAQ
Ticker Symbol MIST
Website https://www.milestonepharma.com
Analyst Forecast
According to 3 analyst ratings, the average rating for MIST stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 355.70% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
4 months ago ·
Source
+2.86%
Milestone Pharmaceuticals shares are trading highe...
Unlock content with
Pro Subscription
